AIM ImmunoTech is trading 7.16% down now at $0.22, with no fresh negative announcement, earnings surprise, or other clear catalyst identified for September 2.
- An August 31 U.S. patent expanded Ampligen-pembrolizumab oncology protection through 2039.
- Recent volatility included a 12.54% decline on August 31 and a 4.42% rebound on September 1.
- Broader futures weakness is modest and does not clearly explain the move.